News
Eisai wins expert panel's approval for new sedative
Backed by a positive review from FDA staffers, an expert panel at the agency has recommended the agency approve Eisai's fospropofol disodium, a sedative designed for use in a number of procedures, Read more...
FDA approves Lilly's ADHD drug Strattera
Eli Lilly has won FDA approval of Strattera, a therapy designed to treat ADHD. Lilly says this is the first regulatory win for a non-stimulant ADHD drug in a market dominated by two Read more...
Traditional remedies offer opportunities, challenges
The Financial Times delves into the push to develop new therapeutics from traditional Chinese and Indian remedies. There have been successes, including the anti-malarial artemether, which was Read more...
Millipore touts its efforts to go green
The life sciences equipment maker Millipore is looking extra green today. The company announced plans to reduce its carbon footprint by 20 percent. To do that, the company plans to close some Read more...
SPOTLIGHT: FDA OKs expanded access for stem cell therapy
Osiris Therapeutics has won approval for an expanded access treatment program for Prochymal, making the Phase III stem cell therapy for graft-vs-host-disease available to children. Read more...
ALSO NOTED: Novartis buys bigger stake in Alnylam; FDA chastises ZymoGenetics' marketing campaign;and much more...
> Novartis has scooped up a bigger share of Alnylam stock. The pharma giant now owns 13.3 percent of the company. Read more...
Enzon spins off biotech ops into $150M enterprise
Enzon Pharmaceuticals has decided to spin off its biotech operations into a new company, adopting a suggestion floated by none other than Carl Icahn. Icahn has Read more...
California grants ignite a boom of lab construction
After four years of litigation and detailed planning, the first $271 million in facilities grants is just about ready to be doled out by the Read more...
Novartis' China plans grew from science roundtables
PharmAsia News sat down with Paul Herrling, head of corporate research at Novartis, and En Li, VP and head of research for Novartis Institutes for BioMedical Research Shanghai, to discuss the Read more...
Astellas faces new delay for Advagraf approval
Japan's Astellas Pharma has run into a new roadblock in its pursuit of regulatory approval of Advagraf, its second generation version of the blockbuster transplant drug Prograf. The FDA has raised Read more...
SPOTLIGHT: Mystery Mistral merger is off
Canada's Mistral Pharma says its proposed merger with an unnamed U.S. specialty pharma company will not be completed. As a result, its bridge financing deal has been canceled and management has Read more...
C&L: Ajit Gill tapped to run Auspex
Ajit Gill has joined Auspex Pharmaceuticals as president and chief executive officer. In conjunction with the recent financing round, Pratik Shah, Ph.D., partner at Thomas, McNerney & Partners, Read more...
ALSO NOTED: BMS: Buyer or buyout target?; LAB Research readies big expansion;Malaysia readies biotech investments; and much mor
> Market-watchers love to speculate. Their latest topic? Bristol-Myers Squibb, which has been paring away its "non-core" businesses over the last few months. Read more...
NicOx shares plunge on Pfizer trial failure
Shares of France's NicOx tumbled 38 percent after Pfizer announced that it would not advance their Read more...
Report: GSK to fund venture firm, back start-ups
In Vivo is reporting that GlaxoSmithKline plans to set aside up to $500 million for a new venture fund that will support its internal R&D work as well as fund start-ups created from Read more...
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight